Baldwin Investment Management LLC Buys 1,271 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Baldwin Investment Management LLC grew its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 10.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,830 shares of the pharmaceutical company’s stock after purchasing an additional 1,271 shares during the period. Vertex Pharmaceuticals makes up about 0.8% of Baldwin Investment Management LLC’s portfolio, making the stock its 12th biggest position. Baldwin Investment Management LLC’s holdings in Vertex Pharmaceuticals were worth $6,705,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of VRTX. GAMMA Investing LLC lifted its stake in shares of Vertex Pharmaceuticals by 60,572.3% in the 1st quarter. GAMMA Investing LLC now owns 2,425,070 shares of the pharmaceutical company’s stock valued at $1,175,722,000 after purchasing an additional 2,421,073 shares during the last quarter. Capital World Investors lifted its stake in shares of Vertex Pharmaceuticals by 5.7% during the 4th quarter. Capital World Investors now owns 28,325,695 shares of the pharmaceutical company’s stock worth $11,406,667,000 after acquiring an additional 1,514,993 shares during the last quarter. Capital Research Global Investors lifted its stake in shares of Vertex Pharmaceuticals by 15.8% during the 4th quarter. Capital Research Global Investors now owns 10,428,951 shares of the pharmaceutical company’s stock worth $4,199,713,000 after acquiring an additional 1,426,746 shares during the last quarter. Edgewood Management LLC lifted its stake in shares of Vertex Pharmaceuticals by 91.2% during the 4th quarter. Edgewood Management LLC now owns 2,956,608 shares of the pharmaceutical company’s stock worth $1,190,626,000 after acquiring an additional 1,410,238 shares during the last quarter. Finally, Wellington Management Group LLP lifted its stake in shares of Vertex Pharmaceuticals by 23.3% during the 4th quarter. Wellington Management Group LLP now owns 5,916,084 shares of the pharmaceutical company’s stock worth $2,382,407,000 after acquiring an additional 1,117,214 shares during the last quarter. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Trading Down 0.6%

Shares of NASDAQ:VRTX opened at $469.65 on Monday. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The business’s fifty day simple moving average is $453.13 and its 200-day simple moving average is $465.42. The company has a market capitalization of $120.61 billion, a PE ratio of -119.81 and a beta of 0.41. The company has a current ratio of 2.65, a quick ratio of 2.29 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing analysts’ consensus estimates of $4.29 by ($0.23). The business had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the business earned $4.76 EPS. As a group, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

VRTX has been the subject of a number of research analyst reports. The Goldman Sachs Group reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. JPMorgan Chase & Co. raised their price target on Vertex Pharmaceuticals from $515.00 to $517.00 and gave the stock an “overweight” rating in a research note on Monday, July 14th. Wolfe Research lowered Vertex Pharmaceuticals from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, May 7th. HC Wainwright reissued a “buy” rating and set a $550.00 price target on shares of Vertex Pharmaceuticals in a research note on Monday, June 23rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Fourteen equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $512.30.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.